Drugs / Polmacoxib
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05370716 | Nov 2019 → Apr 2020 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03774355 | Dec 2018 → May 2019 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03775629 | Dec 2018 → Apr 2019 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01154790 | Jun 2010 → Jan 2011 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01154764 | Oct 2009 → Mar 2010 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00780325 | Oct 2008 → Jul 2013 | — | University of Pennsylvania | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT01341405 | Apr → Dec 2011 | osteoarthritis | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00530452 | Oct 2007 → Sep 2008 | osteoarthritis, hip, osteoarthritis, knee | CrystalGenomics, Inc. | Unknown | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01765296 | Mar → Dec 2013 | osteoarthritis, hip, osteoarthritis, knee | CrystalGenomics, Inc. | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT06590714 | Aug 2024 → Aug 2025 overdue | rotator cuff syndrome | Eulji University Hospital | Recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polmacoxib | “Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.” NCT06590714 ↗3“CGL1802(Polmacoxib 2mg Tablet) and CG1801(Polmacoxib 2mg capsule)” NCT03774355 ↗ |
| Known as | Acelex | “Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.” NCT06590714 ↗ |
| Known as | CG100649 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01341405 ↗ |
| Known as | CG1801 | “CGL1802(Polmacoxib 2mg Tablet) and CG1801(Polmacoxib 2mg capsule)” NCT03774355 ↗ |
| Known as | CGL1802 | “CGL1802(Polmacoxib 2mg Tablet) and CG1801(Polmacoxib 2mg capsule)” NCT03774355 ↗ |
| Action | Inhibit | “Carbonic anhydrase II inhibitor” CHEMBL166863 ↗3“Carbonic anhydrase I inhibitor” CHEMBL166863 ↗ “Dual-acting COX-2 inhibitor” NCT00530452 ↗ “Cyclooxygenase-2 inhibitor” CHEMBL166863 ↗ |
| Modality | Other / unclassified | “CG100649 is a novel NSAID proposed to inhibit both COX-2 and carbonic anhydrase (CA)-I/-II.” PMID 22278334 ↗ Jan 2012 |
| Route | Oral | “Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses” NCT00530452 ↗ |
| Target | CA1 | “Carbonic anhydrase I inhibitor” CHEMBL166863 ↗ |
| Target | CA2 | “Carbonic anhydrase II inhibitor” CHEMBL166863 ↗ |
| Target | PTGS2 | “Cyclooxygenase-2 inhibitor” CHEMBL166863 ↗ |